Abstract:TGF-β and related growth factors activate a broad range of cellular responses and play key roles in the pathogenesis of many diseases especially cancer, fibrotic diseases, autoimmune diseases, and parasitic diseases. The activity of the TGF-β-initiated signaling pathway is tightly controlled, for example, through regulation of the key downstream SMAD tumor suppressors. In response to TGF-β, SMADs are phosphorylated, which triggers a series of downstream signaling and gene transcriptional events in the nucleus. To maintain proper levels of activated SMADs, activated SMADs in the nucleus are normally dephosphorylated by nuclear phosphatase PPM1A and then transported back into the cytoplasm. However, it remains elusive how dephosphorylated SMADs are exported out of the nucleus to ensure the completion of the SMAD signaling termination. Objective: To discover and characterize the underlying pathway that completes the step of SMAD signaling termination. Methods: A combinatorial approach using biochemical, cell biological, and developmental methods was used in this study. Cells were manipulated with expression plasmids for various SMADs, PPM1A, and potential nuclear exporter RanBP3. Xenopus embryos were manipulated using standard protocols. The level of phosphorylated SMADs was performed by western blotting. Nuclear export of SMADs was examined by immunofluorescence microscopy, cell lysate fractionation and a novel reporter assay. Protein-protein interaction of SMADs and RanBP3 was assessed by biochemical assays (e.g. IP-Western) or fluorescence assays. Results: We determined the essential function of RanBP3 in selective nuclear export of SMAD2/3 in the TGF-β pathway. RanBP3 directly recognized dephosphorylated SMAD2/3, which results from the activity of nuclear SMAD phosphatase PPM1A; PPM1A enhanced the physical interaction between RanBP3 and SMAD2/3. We clearly demonstrated that RanBP3 mediated nuclear export of SMAD2/3 in a small G protein Ran-dependent manner. Consequently, increased expression of RanBP3 inhibited TGF-β signaling in mammalian cells and Xenopus embryos, and depletion of RanBP3 expression or dominant negative inhibition of RanBP3 enhanced TGF-β-induced anti-proliferative and transcriptional responses. Finally, we have found that RanBP3 itself was phosphorylated in response to mitogenic growth signals and this phosphorylation could fine-tune the function of RanBP3 in exporting SMADs. Conclusion: We have defined a key role for RanBP3 in selectively mediating SMAD nuclear export and terminating TGF-β signaling. Thus, our finding should provide insights into the mechanisms of TGF-β anti-cancer actions. Knowledge gained from these studies will be used to design novel therapeutic strategies for prevention and treatment of human cancer.

Opposing Roles of TGFβ and BMP Signaling in Prostate Cancer Development

Original Protein tyrosine phosphatase PTPN2 regulates TGF- signaling through Smad4 dephosphorylation

Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer

The role of TGF-β/SMAD4 signaling in cancer

Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development

Bone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway.

Smad4 Sequestered in SFPQ Condensates Prevents TGF-β Tumor-Suppressive Signaling.

SMAD-oncoprotein interplay: Potential determining factors in targeted therapies

Bone Morphogenetic Protein-9 Induces Apoptosis in Prostate Cancer Cells, the Role of Prostate Apoptosis Response-4

[Identification of TGF-beta/Smads Pathway in Human Prostate Cancer Cell Lines and Its Significance].

Bone Morphogenetic Proteins and Their Receptor Signaling in Prostate Cancer.

Multiple pathways coordinating reprogramming of endothelial cells into osteoblasts by BMP4

SMAD4 and Its Role in Pancreatic Cancer

A novel highly potent trivalent TGF-β receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands

TGF-β Tumor Suppression Through a Lethal EMT

TGF-β1 Promotes Epithelial-to-mesenchymal Transition and Stemness of Prostate Cancer Cells by Inducing PCBP1 Degradation and Alternative Splicing of CD44

When BMP Signalling Goes Wrong: the Intracellular and Molecular Mechanisms of BMP Signalling in Cancer

Abstract 2844: BMP inhibition overcomes chemoresistance of prostate cancer

Coupled Actions of PPM1A and RanBP3 Terminate TGFβ/SMAD Tumor Suppressor Functions

Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease

Targeting SMAD3 for Inhibiting Prostate Cancer Metastasis.